Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814879 · ClinicalTrials.gov registry record · NA
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00814879 is a NA study that has completed, run by Yale University. The registered enrollment target is 60 participants.
The verdict
NCT00814879, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.
Interventions
- DRUG Atazanavir
- DRUG Raltegravir
- OTHER Standard treatment regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814879
The ClinicalTrials.gov registry entry for NCT00814879 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atazanavir is the first listed.
NCT00814879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814879 about?
NCT00814879 is a clinical study titled "Pilot Study of a Raltegravir Based NRTI Sparing Regimen". This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are ...
What is the current status of trial NCT00814879?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2009-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00814879?
The interventions under investigation include: Atazanavir (DRUG), Raltegravir (DRUG), Standard treatment regimen (OTHER).
Who is sponsoring clinical trial NCT00814879?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.